Acute bacterial pneumonia in childhood in the current era

Pediatric Annals

Volumn 37, Issue 10, 2008, Pages 694-702

  Woods, Charles R ^a,b  

^a University of Louisville School of Medicine   (United States)

^b NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMOXICILLIN; AMPICILLIN; ANTIBIOTIC AGENT; C REACTIVE PROTEIN; CEPHALOSPORIN; CLINDAMYCIN; COTRIMOXAZOLE; HAEMOPHILUS INFLUENZAE TYPE B VACCINE; INFLUENZA VACCINE; LEVOFLOXACIN; LINEZOLID; MACROLIDE; OXYGEN; PENICILLIN G; PNEUMOCOCCUS VACCINE; PROCALCITONIN; VANCOMYCIN; HAEMOPHILUS INFLUENZA TYPE B POLYSACCHARIDE VACCINE TETANUS TOXIN CONJUGATE; HAEMOPHILUS INFLUENZA TYPE B POLYSACCHARIDE VACCINE-TETANUS TOXIN CONJUGATE; HAEMOPHILUS VACCINE; TETANUS TOXOID; UNCLASSIFIED DRUG;

ABDOMINAL PAIN; ACUTE BACTERIAL PNEUMONIA; ARTICLE; BACTERIAL PNEUMONIA; BLOOD CULTURE; CHLAMYDOPHILA PNEUMONIAE; CLINICAL FEATURE; COMMUNITY ACQUIRED PNEUMONIA; COUGHING; DRUG MEGADOSE; ERYTHROCYTE SEDIMENTATION RATE; EVIDENCE BASED PRACTICE; FEVER; HOSPITAL INFECTION; HUMAN; HYPOXEMIA; IMMUNE RESPONSE; IMMUNOCOMPROMISED PATIENT; INNATE IMMUNITY; LABORATORY TEST; LEUKOCYTE DIFFERENTIAL COUNT; LUNG INFILTRATE; MYCOPLASMA PNEUMONIA; NUTRITIONAL STATUS; ONSET AGE; OXYGEN THERAPY; PATHOGENESIS; PLEURA EMPYEMA; RESPIRATORY VIRUS; SPUTUM CULTURE; STREPTOCOCCUS INFECTION; TACHYPNEA; THORAX RADIOGRAPHY; URINALYSIS; VOMITING; ACUTE DISEASE; ADOLESCENT; CHILD; PRESCHOOL CHILD; REVIEW;

ACUTE DISEASE; ADOLESCENT; CHILD; CHILD, PRESCHOOL; HAEMOPHILUS VACCINES; HUMANS; PNEUMONIA, BACTERIAL; RADIOGRAPHY, THORACIC; TETANUS TOXOID;

EID: 58149291730     PISSN: 00904481     EISSN: None     Source Type: Journal    
DOI: 10.3928/00904481-20081001-11     Document Type: Article

References (45)

1. Williams BC, Gouws E, Boschi-Pinto C, Bryce J, Dye C. Estimates of world-wide distribution of child deaths from acute respiratory infections. Lancet Infect Dis. 2002;2(1):25-32.
2. Mani CS, Murray DL. Acute pneumonia and its complications. In: Long SS, Pickering LK, Prober CG, eds. Principles and Practice of Pediatric Infectious Diseases. 3rd ed. Philadephia, PA: Churchill Livingstone: 2008:245-257.
3. Juvén T, Mertsola J, Waris M, et al. Etiology of community-acquired pneumonia in 254 hospitalized children. Pediatr Infect Dis J. 2000;19(4):293-298.
4. Bryce J, Boschi-Pinto C, Shibuya K, Black RE, WHO Child Health Epidemiology Reference Group. WHO estimates of the causes of the death in children. Lancet. 2005;365(9465):1147-1152.
5. Mulholland K. Childhood pneumonia mortality - a permanent global emergency. Lancet. 2007;370(9583):285-289.
6. Michelow IC, Olsen K, Lozano J, et al. Epidemiology and clinical characteristics of community-acquired pneumonia in hospitalized children. Pediatrics. 2004;113(4):701-707.
7. Hart CA, Beeching NJ, Duerden BI. Respiratory infections: proceedings of the eighth Liverpool Tropical School Bayer symposium of microbial diseases held on 3 February 2001. J Med Microbiol. 2002; 51:903-914.
8. Aherne W, Bird T, Court SD, et al. Pathological changes in virus infections of the lower respiratory tract in children. J Clin Pathol. 1970;23(1):7-18.
9. Heugel J, Martin ET, Kuypers J, Englund J. Coronavirus-associated pneumonia in previously healthy children. Pediatr Infect Dis J. 2007;26(8):753-755.
10. Bastien N, Chui N, Robinson JL, et al. Detection of human bocavirus in Canadian children in a 1-year study. J Clin Microbiol. 2007;45(2):610-613.
11. Zhou F, Kyaw MH, Shefer A, Winston CA, Nuorti JP. Health care utilization for pneumonia in young children after routine pneumococcal conjugate vaccine use in the United States. Arch Pediatr Adolesc Med. 2007;161(12):1162-1168.
12. Pelton SI, Huot H, Finkelstein JA, et al. Emergence of 19A as virulent and multidrug resistant Pneumococcus in Massachusetts following universal immunization of infants with pneumococcal conjugate vaccine. Pediatr Infect Dis J. 2007;26(6):468-472.
13. Martinez-Aguilar G, Hammerman WA, Mason EO, Kaplan SL. Clindamycin treatment of invasive infections caused by community-acquired, methicillin-resistant and methicillin-susceptible Staphlyococcus aureus in children. Pediatr Infect Dis J. 2003;22(7):593-598.
14. Gonzalez BE, Hulten KG, Dishop MK, et al. Pulmonary manifestations in children with invasive community-acquired Staphylococcus aureus infection. Clin Infect Dis. 2005;41(5):583-590.
15. Principi N, Esposito S, Blasi F, et al. Role of Mycoplasma pneumoniae and Chlamydia pneumoniae in children with community-acquired lower respiratory tract infections. Clin Infect Dis. 2001;32(9):1281-1289.
16. Didierlaurent A, Goulding J, Patel S, et al. Sustained desensitization to bacterial Toll-like receptor ligands after resolution of respiratory influenza infection. J Exp Med. 2008;205(2):323-329.
17. Mizgerd JP. Acute lower respiratory tract infection. N Engl J Med. 2008;358(7):716-727.
18. Anderson VM, Turner T. Histopathology of childhood pneumonia in developing countries. Rev Infect Dis. 1991;13(Suppl 6):S470-S476.
19. Cundell D, Gerard N, Gerard C, Idanpaan-Heikkela I, Tuomanen EI. Streptococcus pneumoniae anchors to activated eukaryotic cells by the receptor for platelet activating factor. Nature. 1995;377(6548):435.
20. Bocchini CE, Hulten KG, Mason EO, Gonzalez BE, Hammerman WA, Kaplan SL. Panton-Valentine leukocidin genes are associated with enhanced inflammatory response and local disease in acute hematogenous Staphylococcus aureus osteomyelitis in children. Pediatrics. 2006;117(2):433-440.
21. McCracken GH. Diagnosis and management of pneumonia in children. Pediatr Infect Dis J. 2000;19(9):924-928.
22. Health Policy & Clinical Effectiveness Program. Cincinnati Children's Hospital Medical Center. Evidence-based guideline for children with community acquired pneumonia (CAP). Updated July, 2006. Available at:http://www.cincinnatichildrens.org/svc/alpha/h/health-policy/ev-based/ pneumonia.htm. Accessed on August 22, 2008.
23. Murphy CG, van de Pol AC, Harper MB, Bachur RG. Clinical predictors of occult pneumonia in the febrile child. Acad Emerg Med. 2007;14(3):243-249.
24. Tan TQ, Mason EO Jr, Barson WJ, et al. Clinical characteristics and outcome of children with pneumonia attributable to penicillin-susceptible and penicillin-nonsusceptible Streptococcus pneumoniae. Pediatrics. 1998;102(6):1369-1375.
25. Zukin DD, Hoffman JR, Cleveland RH, Kushner DC, Herman TE. Correlation of pulmonary signs and symptoms with chest radiographs in the pediatric age group. Ann Emerg Med. 1986;15(7):792-796.
26. Tan TQ, Mason EO Jr, Wald ER, et al. Clinical characteristics of children with complicated pneumonia caused by Streptococcus pneumoniae. Pediatrics. 2002;110(1 Pt 1):1-6.
27. Courtoy I, Lande AE, Turner RB. Accuracy of radiographic differentiation of bacterial from nonbacterial pneumonia. Clin Pediatr (Phila). 1989;28(6):261-264.
28. Clements H, Stephenson T, Gabriel V, et al. Rationalised prescribing for community acquired pneumonia: close loop audit. Arch Dis Child. 2000;83(4):320-324.
29. Korppi M, Don M, Valent F, Canciani M. The value of clinical features in differentiating between viral, pneumococcal, and atypical bacterial pneumonia in children. Acta Paediatr. 2008;97(7):943-947.
30. Don M, Valerio G, Korrpi M, Canciani M. Hyponatremia in pediatric community-acquired pneumonia. Pediatr Nephrol. 2008 Jul 8.
31. Panitch HB. Evaluation of recurrent pneumonia. Pediatr Infect Dis J. 2005;24(3):265-266.
32. Don M, Valent F, Korppi M, et al. Efficacy of serum procalcitonin in evaluating severity of community-acquired pneumonia. Scand J Infect Dis. 2007;39(2):129-137.
33. Werno AM, Mundoch DR. Laboratory diagnosis of invasive pneumococcal disease. Clin Infect Dis. 2008;46(6):926-932.
34. Beersma MF, Dirven K, van Dam AP, Templeton KE, Class EC, Goossens H. Evaluation of 12 commercial tests and the complement fixation test for Mycoplasma pneumoniae-specific immunoglobulin G (IgG) and IgM antibodies, with PCR used as the "gold standard." J Clin Microbiol. 2005;43(5):2277-2285.
35. Schmidt SM, Muller CE, Mahner B, Wiersbitzky SK. Prevalence, rate of persistence and respiratory tract symptoms of Chlamydia pneumoniae infection in 1211 kindergarten and school age children. Pediatr Infect Dis J. 2002;21(8):758-762.
36. Gorton CP, Jones JL. Wide geographic variation between Pennsylvania counties in the population rates of hospital admissions for pneumonia among children with and without comorbid chronoc conditions. Pediatrics. 2006;117(2):176-180.
37. McIntosh K. Community-acquired pneumonia in children. N Engl J Med. 2002;346(6):429-437.
38. Haider BA, Saeed MA, Bhutta ZA. Short-course versus long-course antibiotic therapy for non-severe community-acquired pneumonia in children aged 2 months to 59 months. Cochrane Database Syst Rev. 2008:2.
39. Jantausch BA, Deville J, Adler S, et al. Line-zolid for treatment of children with bacteremia or nosocomial pneumonia caused by resistant gram-positive bacterial pathogens. Pediatr Infect Dis J. 2003;22(9 Suppl):S164-S171.
40. Bradley JS, Arguedas A, Blumer JL, Sáez-Llorens X, Melkote R, Noel GJ. Comparative study of levofloxacin in the treatment of children with community-acquired pneumonia. Pediatr Infect Dis J. 2007;26(10):868-878.
41. Shah SS, DiCristina CM, Bell LM, Ten Have T, Metlay JP. Primary early thoracoscopy and reduction in length of hospital stay and additional procedures among children with complicated pneumonia: results of a multicenter retrospective cohort study. Arch Pediatr Adolesc Med. 2008;162(7):675-681.
42. Byington CL, Spencer LY, Johnson TA, et al. An epidemiological investigation of a sustained high rate of pediatric parapneumonic empyema: risk factors and microbiologic associations. Clin Infect Dis. 2002;34(4):434-40.
43. Ampofo K, Byington C. Management of para-pneumonic empyema. Pediatr Infect Dis J. 2007;26(5):445-446.
44. Cohen E, Weinstein M, Fisman DN. Cost-effectiveness of competing strategies for the treatment of pediatric empyema. Pediatrics. 2008;121(5): e1250-e1257.
45. Subramaniam R, Joseph VT, Tan GM, Goh A, Chay OM. Experience with video-assisted thoracoscopic surgery in the management of complicated pneumonia in children. Pediatr Surg. 2001;36(2):316-319.